Compass Point Sees Sallie Mae's (SLM) Green Light for Higher Annual Growth Cap as a Positive - Reiterates Buy

Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)

January 21, 2016 9:28 AM EST

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of... More

Compass Point Reiterates Buy on Sallie Mae (SLM) Following 4Q Earnings and 2016 Guidance

January 21, 2016 7:29 AM EST

Compass Point reiterated a Buy rating and $11.00 price target on SLM Corp. (NASDAQ: SLM) after the company reported better than expected 4Q15 earnings and guidance. The company provided EPS guidance for 2016 of $0.49-$0.51 that, on the surface, looks light compared to consensus of $0.65. However, it is our sense that the guidance... More

After-Hours Stock Movers 01/20: (ECYT) (XLNX) (FEYE) Higher; (OGXI) (SLM) (SRPT) Lower (more...)

January 20, 2016 5:51 PM EST

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.

Endocyte, Inc. (NASDAQ:... More

UPDATE: Sallie Mae (SLM) Tops Q4 EPS by 2c; Guides FY16 Core EPS Below Views

January 20, 2016 4:30 PM EST

(Updated - January 20, 2016 4:34 PM EST)

Sallie Mae (NASDAQ: SLM) reported Q4 EPS of $0.20, $0.02 better than the analyst estimate of $0.18.

Sallie Mae sees FY16 core EPS of $0.49 - $0.51, versus expectations of $0.65.

For earnings history and earnings-related data on Sallie Mae (SLM) click here.

... More

Trading Radar for 1/20: Goldman Sachs (GS), F5 Networks (FFIV), Sallie Mae (SLM), Brinker (EAT) Report

January 19, 2016 2:10 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
7:00am EST

MBA Mortgage Index - no Street consensus

8:30am EST

CPI - Street sees 0.0%Core CPI - Street sees 0.2%Housing Starts - Street sees 1.197MBUilding Permits - Street sees... More